A BuiltForAI Property
Live federal data · NADAC weekly · Part D CY24

Praziquantel Albendazole

Praziquantel vs Albendazole — $9.6M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Anthelmintic
Praziquantel
Brand: Biltricide
First FDA approval:
Anthelmintic
Albendazole
Brand: ALBENZA
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$54.65Per unit
$4.40Per unit
Average NADACAcross all dosage forms and strengths
$54.65Up to $54.65
$4.40Up to $4.40
Generic manufacturersActive ANDA holders — FDA Orange Book
11 total ANDAs filed
66 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$1.8MFull year
$7.8MFull year
Part D claims (CY24)Total fills, all strengths
2K2K beneficiaries
19K14K beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$810Per claim, all NDCs
$414Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
0Zero PA friction
52Minimal friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
0None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
NoneClear
Generic availableFDA Orange Book
Yes1 manufacturers
Yes6 manufacturers